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Abstract
Glioblastomas (GBMs) are fatal WHO grade IV astrocytomas with a median survival of 14.6 months. Immunohistochemical (IHC) studies indicate that cyclophilin 
A (CYPA), and its receptor CD147 are elevated in GBM, but the impacts on disease progression are poorly understood. We determined their occurrence in 
diffuse astrocytomas (WHO grades II-IV) using IHC and evaluated how gene expression affects patient outcomes in The Cancer Genome Atlas (TCGA) and 
REMBRANDT datasets (GBM and Low-Grade-Glioma: LGG). While IHC staining of CYPA was evident across all tumour grades, CD147 staining increased 
with tumour grade. However, while analysis of the TCGA grade II/III tumour dataset showed a trend towards high CD147 gene expression and reduced patient 
survival (HR=2.34, p=0.064, n=132), the results were not statistically significant. By contrast, analysis of the TCGA GBM dataset showed that high CYPA expression 
was significantly associated with reduced survival (HR=1.30, p=0.009; n=593). Furthermore, Kaplan-Meier analysis of both the TCGA and REMBRANDT 
(p=0.052; n=176) GBM datasets showed a comparable reduction in survival of about 3-months for patients with high CYPA expression. We found that CYPA gene 
amplification (≥2.2 copies) occurred in 72% of patients (REMBRANDT GBM dataset) and was correlated with reduced survival (log-rank p = 0.022). Finally, we 
observed a correlation between CYPA and CD147 gene expression in grade II/III (R=0.481, p=1.81x10-6) and grade IV (R=0.132; p=0.0012) tumours. Together, our 
data identify CYPA and CD147 as potential pathogenic determinants in glioblastoma.
Introduction
Glioblastomas (GBMs), otherwise known as grade IV (WHO) 
astrocytomas, are highly proliferative and invasive primary brain 
cancers. Despite aggressive surgery, radiotherapy and adjuvant 
chemotherapy (Temozolomide, TMZ), tumour re-occurrence is 
often rapid, leaving current median survival at just 14.6 months [1]. 
The lack of progress in treating GBMs has meant that patients face 
disproportionate levels of morbidity and mortality compared to other 
cancers [1]. Arguably, improving survival rates in GBM patients will 
be contingent on finding clinically relevant disease determinants for 
therapeutic targeting. Cyclophilin A (CYPA) and its receptor CD147, 
which we previously reported are potent and interacting cytoprotectants 
[2-5], are two cancer determinants, which were recently linked to GBM 
[6-14]. 
Cyclophilin A, an ubiquitous intracellular/extracellular isomerase 
and cyclosporine (CsA) target, is implicated in protein folding/
trafficking, cell-signalling, apoptosis and cytoprotection [2,3,15]. 
Inhibiting CYPA blocks IL-8 release and tumour growth of U87 cells 
[10], while enhancing cisplatin toxicity in C6 glioma cells [9,16]. 
Further, the expression of its receptor CD147, a glycosylated membrane-
bound immunoglobulin [3], is reportedly elevated in 80% of paediatric 
and adult gliomas [8,11]. CD147 expression reportedly increases with 
tumour grade [6,17], and in paediatric gliomas, correlates with matrix 
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metalloproteinase 2 (MMP2) and CD44 expression [8,11]. Finally, in 
vitro studies have revealed that CD147 knockdown inhibits glioma 
cell migration and MMP secretion [18]. Importantly, these CD147 
related functions are likely to influence the invasive properties of GBM 
cells. While recent studies report that CYPA and CD147 are elevated 
in GBM [10,13,14], their role in disease progression and occurrence 
in lower grade gliomas remains unclear. Added to this, evidence has 
emerged indicating that CYPA and CD147 can interact to promote 
tumourigenesis [19].
To date, the limited numbers of studies reporting CYPA and CD147 
expression in GBM have predominantly relied on immunohistochemical 
(IHC) data. While useful, IHC is only semi-quantitative, with staining 
levels confined to simple categories (e.g. 0-3). Thus, adopting IHC 
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These datasets were previously validated [24,25] and certified for 
use without limitation (http://cancergenome.nih.gov/publications/
publicationguidelines). The GBM cohort of 593 patients comprised 360 
men and 233 women (mean age 57.7 years), with 457-recorded deaths 
from all causes, at the time of the study. The cohort of 132 patients 
with astrocytoma consisted of 70 men and 62 women (mean age 44.5 
years) comprising grade II (n=43) and grade III (n=89) tumours, with 
26-recorded deaths from all causes, at the time of the study. It should 
be noted that the TCGA datasets denoted as low-grade or lower grade 
glioma (LGG) included WHO grade II/III astrocytomas. Data from 
the Repository for Molecular BRAin Neoplasia DaTa (REMBRANDT) 
National Cancer Institute 2005, was analysed using the REMBRANDT 
web-based interface for simple calculations, accessed 2014 April 30. 
The original REMBRANDT database is now accessible via the link: 
https://gdoc.georgetown.edu/gdoc/workflows/index.
Statistical and bioinformatics analyses
The GBM and astrocytoma cohorts from The Cancer Genome 
Atlas (TCGA) [26] were statistically analysed using the R programming 
environment [27]. Kaplan-Meier survival curves showing the 
prognostic significance of CYPA and CD147 overexpression, were 
produced using the R “survival” package. Cox regressions were 
calculated using the R “coxph” function from the “survival” package 
with ties addressed by Efron’s method. For both Cox regressions and 
Kaplan-Meier survival curves, all deaths were used as an endpoint. As 
indicated, analyses were adjusted for age and gender. The validity of 
proportional hazards assumptions were assessed by scaled Schoenfeld 
residuals [21]. Correlation coefficients were calculated using the R “cor.
test” function and a simple linear model fitted to CYPA and CD147 
expression data using the “lm” function. 
Kaplan-Meier and gene copy number data from REMBRANDT 
were analysed using the REMBRANDT web-based interface and 
downloaded without manipulation (Figure 3b; Figure 4). Copy number 
was measured using the SNP 100K chip data. The REMBRANDT GBM 
data set provided expression intensities for all 8 CYPA probe tested. 
The median expression intensity for all CYPA Affymetrix probes was 
8.11 (range: 6.7 - 9.7; standard deviation of 1.3), meaning all probes 
reported a similar CYPA expression. The CYPA gene copy number 
versus patient survival data reported in Figure 4, was derived from 
probe 217602_at, which had an expression intensity of 8.97, was close 
to the mean intensity value for all probes.
Microscopy and imaging 
Microscopy and imaging: Image acquisition was performed using 
an Olympus IX70 microscope fitted with a cooled CCD digital camera 
(DP70; Olympus, Japan) under software control (DP controller; 
Olympus).
Results
Staining of CYPA and CD147 in astrocytoma (WHO grades 
II-IV)
Astrocytoma tumour sections (N=30) were stained for CYPA and 
CD147 (Table 1, Figure 1). CD147 staining was moderate-to-strong in 
GBM tissue, moderate in WHO grade III analplastic astrocytoma and 
mostly undetectable in WHO grade II diffuse astrocytomas (N=13). 
Based on these data, CD147 staining increased with tumour grading. 
Cyclophilin A staining was moderate-to-strong in GBM (N=14), 
moderate in grade III (N=3) and weak-to-moderate in grade II (N=13) 
astrocytoma. Compared to CD147, while CYPA staining increased 
with tumour grade, the delineation between grades was less marked.
to correlate candidate tumour gene expression and patient survival 
comes with caveats. Also, while increased CD147 staining is reportedly 
prognostic [14] in GBM, staining intensity may not necessarily equate 
with actual changes in protein levels. This is because the contribution of 
CD147 to tumorigenesis appears to correlate with the degree of receptor 
glycosylation [17,20,21], which is independent of protein expression. 
Similarly, while the cytokine behaviour of CYPA may be a contributing 
factor in GBM pathogenesis, as is reported for other malignancies 
[12,19,22], its extracellular location means it is unlikely to be detected 
by IHC.
The availability of high quality tumour specific genetic data in large 
depositories like The Cancer Genome Atlas (TCGA) and REMBRANDT 
can provide powerful quantitative evidence to corroborate and/or 
inform the findings of IHC studies. Thus, this study evaluated CYPA 




The Western Australian, state government pathology service, Path 
West, provided archived astrocytoma (confirmed pathology) and non-
neoplastic brain tissue. All subjects gave their informed consent for 
inclusion before they participated in the study. The study was conducted 
in accordance with the declaration of Helsinki and the permission to use 
human tissue was granted by the Sir Charles Gairdner Group, Human 
Research Ethics Committee (approval #2009-016).
Immunohistochemistry
Gliomas were classified and graded according to current World 
Health Organisation (WHO) Guidelines [23]. Specimens were received 
fixed in 10% buffered neutral formalin, assessed macroscopically 
and routinely processed into paraffin embedded blocks. Following 
processing, 4μm sections of tissue were cut, transferred onto glass slides, 
deparaffinized, re-hydrated and subjected to antigen retrieval. Sections 
were probed with rabbit polyclonal anti-CYPA antibody (1:3000, 
Biomol, USA) or mouse monoclonal anti-CD147 (1:10000, Santa Cruz, 
USA). Anti-mouse and anti-rabbit HRP-tagged secondary antibodies 
were used according to the manufacturers instructions (EnVisionTM 
DAKO, USA). Sections were stained with 3,3’-diamino-benzidine and 
counterstained with Haematoxylin. 
Analysis of tissue immunoreactivity
Tissue sections were scored according to the method of Gu et al 
[8]. In brief, the numbers of cells showing membrane and cytoplasmic 
staining from ten representative microscope fields were totalled. The 
percentage immunoreactivity was determined for each tissue section 
and a semi-quantitative value was derived according to the following 
scheme: 0 = absent/<5%; 1+ = weak/6-25%; 2+ = moderate/26-50% and; 
3+ = strong/>51%.
Publicly available datasets
To investigate the clinical significance of CYPA and CD147 mRNA 
overexpression in GBM, we downloaded the clinicopathologic and 
intratumoral mRNA expression data from 593 Glioblastoma (GBM) 
and 132 Low Grade Glioma (LGG) astrocytoma patient datasets at 
The Cancer Genome Atlas (TCGA) (https://tcga-data.nci.nih.gov/
tcga/tcgaDownload.jsp; accessed October 2013). The intratumoral 
mRNA levels provided were measured using Illumina HiSeq 2000 
RNA Sequencing Version 2 and were subsequently normalised. 
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By contrast, CD147 gene expression in grade III astrocytoma 
correlated with reduced patient survival (HR 2.34, p=0.064; n=132) 
when compared to grade II astrocytoma. Within the astrocytoma grade 
III cohort, Kaplan-Meier analysis of patient survival returned a hazard 
ratio of 1.92 (p=0.14, n=89) for high expression of CD147 compared to 
low CD147 gene expression (Figure 2). In this instance, the number of 
patients was relatively small and the results were not significant. 
A Pearson's correlation coefficient determination revealed a strong 
correlation between CD147 and CYPA expression in astrocytoma grade 
III (R = 0.481 and a p-value of 1.81 x 10-6; data not shown). In other 
words, high CD147 gene expression was associated with high CYPA 
gene expression. 
 
Figure 1. Immunohistochemical staining of glioblastoma tissue. Formalin fixed, paraffin 
embedded sections (4 μm) were probed with either anti-CYPA or anti-CD147 antibodies 
and stained with DAB and counterstained with haematoxylin (image magnification 100x). 
Panels a) Non-neoplastic brain tissue (anti-CYPA 1:3000); b) GBM tissue (anti-CYPA 
1:3000); c) Non-neoplastic brain tissue (anti-CD147, 1:10000), note the endothelial cell 
staining; d) GBM tissue (anti-CD147, 1:10000).
Figure 2. Kaplan-Meier analysis of CD147 expression in astrocytoma grade III. High 
CD147 expression returned a HR value of 1.92 (p=0.14, n=89) relative to low CD147 
expression. As only 2 deaths were recorded for grade II astrocytoma patients, a Kaplan-
meier analysis was not performed.
Figure 3a. Kaplan-Meier Survival Plot of CYPA Gene Expression in GBM. Analysis of 
the TCGA GBM dataset showed CYPA gene expression correlated with decreased overall 
percent survival (log-rank p = 0.009) adjusted for age and gender. The solid and dotted 
plot-lines correspond to low (399 patients) and high (194 patients) CYPA gene expression 
respectively.
Figure 3b. Kaplan-Meier Survival Plot of CYPA Gene Expression in GBM. Analysis of 
the REMBRANDT GBM dataset showed that high CYPA gene expression was correlated 
with decreased probability of survival (log-rank p = 0.052). The yellow and red plot-
lines correspond to intermediate (114 patients) and upregulated (62 patients) CYPA gene 
expression respectively
Analysis of CYPA and CD147 gene expression in grade II/III 
astrocytomas 
To test our IHC findings, we analysed grade II/III astrocytoma 
(N=132) expression data (low-grade glioma: LGG cohort, accessed 
April 2014) from the The Cancer Genome Atlas (TCGA) network [28]. 
For both genes, there was a slight (but non-significant), 1.04 fold higher 
expression level in grade III tumours compared to grade II tumours 
(CYPA, p=0.25; CD147, p=0.498; n=132). Cox-regression analysis of 
CYPA expression (adjusted for age and gender) showed that the slight 
difference between grade II and grade III tumours did not affect overall 
survival (HR=0.9, p=0.81; n=132, Table 2).
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Analysis of CYPA and CD147 gene expression in GBM
Cox-regression analysis of CYPA and CD147 gene expression data 
from the TCGA GBM cohort (N=593; Table 3) using multivariate 
analysis (adjusted for age and gender) showed that high CYPA 
expression was associated with reduced patient survival compared to 
low CYPA expression (Hazard Ratio: HR, of 1.30, p=0.009, N=593).
Kaplan-Meier survival plots for CYPA showed that high expression 
decreased median patient survival by approximately 3 months (Figure 
3a). To test these findings, we analysed CYPA and CD147 gene 
expression (N=176) in a second GBM dataset, the REMBRANDT 
database. 
We found strong agreement with the TCGA dataset, in that higher 
CYPA expression was associated with a reduction in median patient 
survival (p=0.052) of 85 days or 2.75 months (Figure 3b). CD147 gene 
expression was not associated with reduced patient survival (HR 1.06 
p=0.860, 0.76-1.26).
CYPA and CD147 gene expression were highly correlated (Pearson’s 
correlation score was 0.132; p=0.002, n=593; Figure 3c). 
CYPA gene copy number correlates with patient survival
The consistent distribution pattern of CYPA gene expression, 
viz. 33% and 67% (high versus low, respectively) and patient survival 
observed in both GBM datasets suggested a potential genetic origin. 
To explore this possibility, we derived a Kaplan-Meier survival 
plot as a function of CYPA gene copy number using data from the 
REMBRANDT dataset. We found that the CYPA gene was amplified 
by ≥ 2.2 copies in 72.2% of patients (determined using the AFFymetrix 
reporter: 217602_at) and that this increase significantly correlated with 
reduced patient survival (log rank p-value of 0.022, n=90; Figure 4). It 
should be noted that the AFFymetrix reporter: 217602_at maps to the 
first intronic sequence of the human Ppia gene.
Discussion
A key finding of this study is that CYPA gene expression is 
predictive of patient outcome. Specifically, multivariate cox-regression 
and Kaplan-Meier analysis of CYPA gene expression in the TCGA 
and REMBRANDT GBM datasets revealed a statistically significant 
relationship between high CYPA expression and reduced overall patient 
survival. We found substantial consistency across both GBM datasets, 
Figure 3c. Scatter-plot of CYPA and CD147 expression in GBM. Analysis of CYPA and 
CD147 TCGA data n=593, cor=0.129, p=0.002





























Grade 2 & 3 132 26
 High CD147 2.34 0.064 0.95-5.75
 High CYPA 0.90 0.81 0.40-2.03
Grade 2 43 2 Too few
 High CD147 deaths
 High CYPA
Grade 3 89 24
 High CD147 2.03 0.16 0.76-5.45
 High CYPA 0.97 0.94 0.41-2.31
Table 2: Multivariate Cox regression analyses showing overall survival by gene expression 













interval of HR 
(adjusted)
CD147 1.06 (p=0.661) 0.82-1.37 1.06 (p=0.860) 0.76-1.26
CYPA 1.24 (p=0.031) 1.02-1.51 1.30 (p=0.009) 1.07-1.58
Table 3: Univariate and multivariate Cox regression analysis of overall survival by gene 
expression in patients with glioblastoma.
Figure 4. Kaplan-Meier Survival Plot of CYPA gene Copy Number in GBM. Analysis 
of the REMBRANDT GBM dataset showed CYPA gene copy amplification (>2.2 copies) 
decreased the probability of patient survival (log-rank p = 0.022). The yellow and red plot-
lines correspond to intermediate (25 patients) and upregulated (65 patients) samples
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where a third of all patients had tumours with high CYPA expression 
and that median survival among this group was reduced by about 3 
months. By contrast, a comparison of CYPA staining in GBM and 
low-grade astrocytoma was less clear, although a weak correlation was 
suggested. For example, while staining intensity was generally robust 
in GBM and grade III astrocytomas, CYPA staining was also evident 
in grade II astocytomas. Similarly, CYPA gene expression showed no 
association between tumour grade and overall patient survival in the 
TCGA LGG dataset. Thus, while differential CYPA gene expression 
can predict GBM patient outcome, it cannot distinguish between low-
grade glioma (grade II/III astrocytoma) and GBM. While elevated 
CYPA expression has been previously noted in GBM tissue using IHC 
[10], this is the first study to link especially high gene expression with 
reduced survival.
As CYPA is encoded on chromosome 7, a chromosome frequently 
amplified in GBM isolates (29), we asked if CYPA amplification could 
account for the difference in gene expression observed. However, we 
found that increased CYPA copy number, which occurred in >72% of 
patients (according to REMBRANDT), did not equate with the 33% 
of patients that showed particularly high CYPA gene expression. Not 
surprisingly, the genetic origins of CYPA gene expression in GBM are 
more complex and are likely to involve regulatory, transcriptional and 
gene dosage effects. 
Consistent with previous reports [13,14,30] we observed robust 
CD147 staining in GBM tissue. However, we found no difference in 
patient survival (TCGA and REMBRANDT) between high and low 
CD147 gene expression. Our findings are in line with a colorectal cancer 
study that showed an association between CD147 staining and tumour 
severity, but not between mRNA levels and tumour severity [31]. The 
extent to which CD147 is glycosylated, which purportedly increases with 
tumour grade and virulence [21], may account for the disparity between 
our gene expression data and the findings described in IHC studies 
[13,14,30]. In this instance, the correlation between differential staining 
intensity and malignancy may arise if the antibodies used exhibited a 
greater affinity for glycosylated CD147. This notion is supported by 
the work of Reithdorf et al (2006) who showed that removing specific 
carbohydrate moieties from glycosylated CD147 could alter and even 
abolish antibody reactivity [17]. Nonetheless, as CD147 staining was 
evident in grade III astrocytomas and GBMs, but virtually absent in 
grade II astrocytomas, we suggest that CD147 staining could be used 
to distinguish grade II astrocytomas from grade III astrocytomas and 
GBMs. This view is also supported by our multivariate analysis of 
CD147 gene expression of the LGG (TCGA) dataset which showed 
that CD147 expression was associated with a HR of 2.34 for grade III 
tumours (p=0.064; n=132) compared to grade II tumours. Within the 
astrocytoma grade III cohort, Kaplan-Meier analysis of patient survival 
returned a hazard ratio of 1.92 (p=0.14; n=89) for high expression 
compared to low CD147 expression. However, the number of patients 
was relatively small and the value was not significant.
This study also revealed a correlation between CD147 and CYPA 
expression in both the GBM (R=0.132; p=0.002) and LGG datasets (R 
= 0.481; p=1.81 x 10-6). To our knowledge this study is the first study 
to report such a finding in GBM, or for any human disease, including 
other malignancies. This is despite considerable experimental evidence 
that CYPA and CD147 participate and/or interact in many disease 
related pathways [19]. Although interesting, the association between 
CYPA and CD147 expression remains speculative as the molecular 
basis for this interaction was not investigated. Nonetheless, previous 
studies suggest that transcriptional activation of both CYPA and 
CD147, could arise via the hypoxia inducible factor (HIF) [32,33] and/
or the transcription factor Sp1 [33]. Evidence also suggests that CYPA 
directly increases CD147 expression, at least in cholangiocarcinoma 
cells [19]. Finally, that CYPA and CD147 share a regulatory pathway(s) 
warrants further investigation. 
As HIF mediates transcriptional activation of CYPA expression, 
a potentially novel pathway linking CYPA and CD147 could involve 
hypoxic and/or oxidative stress induced secretion of CYPA [34,35]. 
As activation of the HIF pathway is a driver of tumour growth and 
angiogenesis in GBM [36,37], it would be interesting to determine 
if GBM cells, like other cancer cells [19], can secrete CYPA. In this 
scenario, extracellular CYPA could contribute to GBM tumourigenesis 
by activating pro-survival signaling [2,4,38], cell proliferation [19], cell 
invasion/migration [39-41] and MMP release [42], presumably via the 
CD147 receptor. Interestingly, extracellular CYPA has been detected 
in the CSF of patients with diffuse pontine glioma [43] and in an 
experimental model of prion disease [44]. 
While the true impacts of CYPA on GBM progression awaits 
full investigation, studies have identified potent tumourigenic 
properties for CYPA that include: abrogating hypoxic stress [2,3], 
enhancing chemoresistance [10,45,46] supporting cell-proliferation 
and invasiveness [10,46,47] and invoking inflammatory/angiogenic 
cytokine release [48-50]. Likewise, the tumourigenic consequences of 
CD147 receptor activation (either by homo-dimer formation or CYPA 
binding) are also extensive and include the activation of the MAPK 
(ERK1/2, p38, and JNK), PI3/Akt and NF-κB signalling pathways which 
can lead to pro-survival signalling, cytokine release, cell migration 
and proliferation [2,3]. Added to these, CD147 can also exert non-
CYPA related tumourigenic impacts such augmenting CD44/EGFR 
signaling and critically, in trafficking the oncogenic monocarboxylate 
proteins, MCT1 and MCT4 [11]. Finally, a recent study showed that 
CYPA actually promotes glioma-initiating cell stemness, self-renewal, 
proliferation and radioresistance via Wnt/B-catenin signaling [51]. If 
confirmed, it would demonstrate a potentially critical role for CYPA 
in glioblastoma development, recurrence and treatment resistance, 
consistent with the present findings.
Conclusion 
Our findings highlight the need to consider both IHC and gene 
expression data when assessing the relevance of a given disease 
determinant/marker. Our findings also reveal that CYPA gene expression 
is an independent prognostic factor of patient outcome in GBM and a 
potential therapeutic target that warrants further investigation. 
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